

Gene Therapy in Modern Medicine: Promises and Challenge in Treating Genetic Diseases

Pritam Kumar Saini*

Abstract

Gene therapy is a medical approach that focuses on altering or adjusting an individual's genes to treat or prevent illnesses. The aim is to repair faulty genes or insert new ones into the body to combat diseases. Gene therapy can involve directly introducing modified or new genes into a patient's cells or altering the genes already present in the patient's body. This approach shows potential for treating a range of conditions, including genetic disorders like cystic fibrosis and sickle cell anemia, as well as certain forms of cancer. Although gene therapy has shown promise in clinical trials, challenges, such as delivery methods, immune responses, and ethical considerations remain significant obstacles to its widespread use. Modern medicine has witnessed transformative advancements, particularly in the field of gene therapy, a cutting-edge approach aimed at treating or potentially curing genetic disorders at their source. Unlike traditional treatments that focus on managing symptoms, gene therapy targets the root cause of disease by correcting or modifying defective genes within a patient's cells. Techniques, such as viral vector delivery, CRISPR-Cas9, and RNA-based therapies enable precise alterations in the genetic code, offering hope for inherited disorders, cancers, and even infectious diseases. Recent clinical successes, including treatments for spinal muscular atrophy, hemophilia, and certain forms of blindness, highlight gene therapy's potential to reshape therapeutic approaches. Despite these advancements, significant challenges persist in guaranteeing the safety, effectiveness, and worldwide accessibility of gene therapies. Issues, such as immune responses to vectors, ethical concerns, high treatment costs, and regulatory complexities pose significant obstacles. However, ongoing research and advances in genome-editing technology, vector design, and delivery systems continue to enhance the safety and scope of gene therapy, paving the way for broader applications in modern medicine, and a new era of personalized, precision healthcare.

Keywords: Gene editing, CRISPR-Cas9, genetic disorders, gene delivery, adenovirus vectors, lentivirus vectors, somatic gene therapy

INTRODUCTION

Gene therapy is a cutting-edge medical approach designed to treat or prevent diseases by directly altering the genes within a patient's cells. Unlike conventional treatments that focus on managing symptoms, gene therapy addresses the root genetic causes of diseases, providing the possibility of long-term or even permanent solutions.

*Author for Correspondence

Pritam Kumar Saini
E-mail: pritamsaini082@gmail.com

Student, Department of Life Science Botany, Raj Rishi Govt. College, Alwar, Rajasthan, India

Received Date: November 09, 2024
Accepted Date: November 28, 2024
Published Date: December 24, 2024

Citation: Pritam Kumar Saini. Gene Therapy in Modern Medicine: Promises and Challenge in Treating Genetic Diseases. International Journal of Genetic Modifications and Recombinations. 2024; 2(2): 27–32p.

Gene therapy has evolved remarkably since its inception, transforming from a bold, experimental idea into a promising reality in modern medicine. Early explorations of gene therapy in the 1970s and 1980s were fueled by discoveries in molecular biology that unveiled the fundamental structure and function of DNA. Initial experiments focused

on modifying genes in laboratory settings, using basic viral vectors to introduce genetic material into cells [1]. These pioneering studies laid the groundwork, but early clinical trials often faced significant setbacks due to issues, such as immune reactions, limited efficacy, and safety concerns (Figure 1).

The field saw a major turning point in the late 1990s and early 2000s, with improved understanding of viral vectors, especially retroviruses and adenoviruses, which were optimized to carry therapeutic genes safely. However, it wasn't until recent years, with the development of precise genome-editing tools like CRISPR-Cas9, that gene therapy began achieving more reliable, targeted results. CRISPR-Cas9 enables scientists to edit genes with high accuracy, offering the potential to not only replace defective genes but to repair them directly within the genome [2]. Additionally, advancements in nonviral delivery methods, such as lipid nanoparticles and synthetic vectors, have expanded the range of diseases treatable by gene therapy, while reducing risks associated with viral approaches (Figure 2).




Figure 1. Gene identification, gene editing/modification, gene delivery, integration into the genome, therapeutic outcome.

ADVANTAGE OF GENE THERAPY

1. *Treatment at the Source:* Gene therapy addresses diseases at their genetic root by correcting or modifying faulty genes.
2. *Potential for Curing Genetic Disorders:* Many inherited diseases, such as cystic fibrosis, hemophilia, and muscular dystrophy, have no cure and rely on symptom management. Gene therapy offers a chance to cure these conditions by correcting defective genes, giving patients a chance for a healthier life.
3. *Cancer and Rare Disease Treatment:* Gene therapy is revolutionizing cancer treatment by engineering immune cells to target and destroy cancer cells.
4. *Long-Lasting Effects:* In many cases, gene therapy can provide sustained or permanent improvements with just a single treatment [3, 4].




Figure 2. Normal gene expression vs. dysregulated gene expression in monogenic disorders.

DISADVANTAGES OF GENE THERAPY

1. *Safety and Side Effects:* Gene therapy involves complex procedures, and some of the potential side effects can be severe. For example, inserting a new gene could trigger an immune response, leading to inflammation, tissue damage, or even serious complications like organ failure.
2. *Unintended Genetic Changes:* Techniques like CRISPR allow precise gene editing, but errors can still occur. These “off-target” changes may accidentally alter other genes, potentially causing unintended consequences, such as new mutations, cancer, or other diseases.
3. *High Cost:* Gene therapy treatments are currently among the most expensive in the world. For instance, certain one-time gene therapies can cost millions of Rupees and dollars.
4. *Ethical and Social Concerns:* Modifying human genes raises ethical issues, especially with technologies that could affect future generations. Concerns about “designer babies,” genetic inequality, and altering the human genome’s natural course led to intense ethical debates [5].

CAUSE AND EFFECT

The primary “cause” or driving factor for gene therapy is the presence of genetic mutations or abnormalities that lead to disease. When a gene is missing, mutated, or malfunctioning, it disrupts normal cellular function and can result in serious health conditions. Replacing faulty genes: Introducing a healthy copy of a gene to replace a defective one.

Inactivating problematic genes: “Silencing” genes that are functioning abnormally and causing harm.

- *Introducing New Genes:* Adding genes to help fight diseases or boost the body's ability to respond to health challenges, such as by enhancing the immune response to cancer cells.
- *Effect: Side Effects and Health Risks:* While beneficial, gene therapy can also lead to unintended side effects, such as immune reactions, off-target genetic changes, and organ damage.
- *Impact on Future Generations (for Germline Therapy):* In therapies that alter the germline (sperm or egg cells), changes can be passed down to future generations.
- *Enhanced Quality of Life:* With reduced symptoms or complete cures, patients experience a better quality of life. For instance, people with hemophilia, a genetic blood disorder, have seen reduced bleeding episodes and a decreased need for regular blood transfusions after gene therapy.

Problem: 1. Immune Response to Gene Delivery Vectors

- *Issue:* Most gene therapies use viral vectors to deliver genetic material into the cells, but the immune system may recognize these viruses as threats and mount an immune response, reducing treatment effectiveness and potentially causing adverse reactions.
- *Solution:* Researchers are developing safer, non-viral vectors and optimizing viral vectors to reduce immunogenicity. Additionally, administering immunosuppressive drugs during therapy can help lower immune reactions. Another approach involves engineering viral vectors specifically to evade immune detection [6].

Problem: 2. Short-Lived Effects for Some Therapies

- *Issue:* While some gene therapies are designed to be permanent, others may not last as long due to factors like cell turnover or immune system reactions. This can mean patients may need repeated treatments, which adds risks and costs.
- *Solution:* Advances in gene-editing technology, such as integrating the gene directly into the patient's DNA, could improve the durability of the treatment. Researchers are also investigating the use of stem cells as delivery vehicles, which could provide more durable effects [7].

Problem: 3. Limited Understanding of Long-Term Effects

- *Issue:* Since gene therapy is a relatively new field, we lack data on its long-term effects. There is a risk that unknown side effects could emerge years after treatment, impacting patients' health in unforeseen ways.
- *Solution:* Long-term monitoring of patients who have received gene therapy can help gather essential data on side effects and outcomes. Establishing patient registries and conducting follow-up studies can help researchers identify and address any emerging issues over time [8].

Examples: 1. Luxturna (Voretigene Neparvovec)

Is a gene therapy approved for treating inherited retinal diseases caused by mutations in the RPE65 gene? This therapy delivers a functional copy of the gene directly to the retina, which can restore vision or slow the progression of blindness in patients with certain inherited forms of retinal dystrophy.

- *Zolgensma (Onasemnogene Apeparvovec):* Zolgensma is a gene therapy used to treat spinal muscular atrophy (SMA), a genetic condition that leads to severe muscle weakness and respiratory issues. It works by replacing the missing or defective SMN1 gene in patients, providing the body with the correct instructions to produce the survival motor neuron protein.
- *Kymriah (Tisagenlecleucel):* Kymriah is a CAR-T cell therapy used to treat certain blood cancers, including acute lymphoblastic leukemia (ALL) and large B-cell lymphoma. It involves altering a patient's own T-cells to express a chimeric antigen receptor (CAR), which enhances the immune system's ability to identify and destroy cancer cells [9].
- *Strimvelis:* Strimvelis is a gene therapy designed for patients with severe combined immunodeficiency caused by adenosine deaminase (ADA) deficiency. The therapy involves introducing a functional copy of the ADA gene into the patient's hematopoietic stem cells,

allowing the immune system to function correctly.

- *Glybera (Alipogene Tiparvovec)*: Glybera was the first gene therapy approved in Europe for treating lipoprotein lipase deficiency (LPLD), a rare genetic disorder that leads to severe pancreatitis. It works by inserting a healthy copy of the LPL gene into the patient's muscle cells to restore the enzyme's function (Figure 3) [10].




Figure 3. Overview of gene therapy approaches: In Vivo, Ex Vivo, and In Situ strategies.

CONCLUSIONS

Gene therapy represents a transformative approach in modern medicine, targeting diseases at their genetic root to offer potential cures or long-lasting treatments. By replacing, repairing, or modifying faulty genes, it opens up new possibilities for treating genetic disorders, certain cancers, and other diseases that are difficult to manage with traditional methods. Despite its incredible promise, gene therapy faces challenges, including delivery difficulties, high costs, immune reactions, and ethical concerns about altering human DNA.

Advances in technology, such as precision gene-editing tools and innovative delivery systems, are addressing many of these hurdles, making gene therapy safer, more effective, and more accessible.

As research progresses, gene therapy is expected to expand its reach and applicability, bringing hope to millions affected by previously untreatable or incurable conditions. While it may take time to fully overcome current challenges, gene therapy remains a key area of medical innovation, potentially reshaping healthcare by addressing the genetic causes of disease.

Today, gene therapy is at the forefront of medical innovation, with numerous therapies receiving regulatory approval and transforming lives by providing new options for previously untreatable genetic diseases. The journey from early, rudimentary approaches to the sophisticated gene-editing technologies available today highlights the relentless pursuit of safer, more effective ways to harness the power of our genetic code to combat disease. This evolution reflects both the incredible potential of gene therapy and the complex scientific, ethical, and technical challenges that continue to drive the field forward.

Acknowledgments

This acknowledgment highlights the collective efforts and contributions across various sectors of the field.

“We would like to express our deepest gratitude to all the researchers, clinicians, and scientists whose groundbreaking work has paved the way for advancements in gene therapy. Special thanks to

the dedicated medical professionals who work tirelessly to implement these therapies in clinical settings, and to the patients who participate in clinical trials, making invaluable contributions to the field. We also acknowledge the funding organizations, laboratories, and research institutions that provide the resources and support necessary for this work. Finally, our sincere thanks to the families and communities affected by genetic disorders, whose resilience and hope continue to inspire the pursuit of innovative treatments in gene therapy.”

REFERENCES

1. Yan W, Wang P, Zhao CX, Tang J, Xiao X, Wang DW. Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor- β /Smad and p38 mitogen-activated protein kinase signaling pathways. *Human Gene Ther.* 2009;20(10):1190–200. doi: 10.1089/hum.2008.204.
2. Jahanyar J, Joyce DL, Southard RE, Loebe M, Noon GP, Koerner MM, et al. Decorin-mediated transforming growth factor- β inhibition ameliorates adverse cardiac remodeling. *J Heart Lung Transplant.* 2007;26(1):34–40. doi: 10.1016/j.healun.2006.10.005.
3. Li L, Okada H, Takemura G, Kosai KI, Kanamori H, Esaki M, et al. Postinfarction gene therapy with adenoviral vector expressing decorin mitigates cardiac remodeling and dysfunction. *Am J Physiol Heart Circ Physiol.* 2009;297(4):H1504–H1513.
4. Somia N, Verma IM. Gene therapy: Trials and tribulations. *Nat Rev Genet.* 2000;1(2):91–99. doi: 10.1038/35038533.
5. Niewöhner J, Tannert C, editors. *Gene therapy: Prospective technology assessment in its societal context.* Elsevier; 2011.
6. Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: An update. *J Gene Med.* 2018;20(5):e3015. doi: 10.1002/jgm.3015.
7. Capone F, Nappi F, Galli MC. Gene therapy clinical trials: past, present and future. In: *Second generation cell and gene-based therapies.* Academic Press; 2020. pp. 285–301.
8. Arjmand B, Larijani B, Sheikh Hosseini M, Payab M, Gilany K, Goodarzi P, et al. The horizon of gene therapy in modern medicine: Advances and challenges. *Adv Exp Med Biol.* 2020;1247:33–64. doi: 10.1007/5584_2019_463.
9. Adi-Dako O, Kumadoh D, Pathak YV, Gyamerah NK. Overview of Development of Gene Therapy. In: *Gene Delivery Systems.* 2022. pp. 1–20.
10. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. *Nat Med.* 2001;7(1):33–40. doi: 10.1038/83324.